oasis-1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial oasis-1 oral semaglutide 50 mg – JAMA Internal Medicine on X:

For decades, researchers focused almost exclusively on the physical consequences of obesity while largely ignoring its profound psychological impact

It activates the tyrosine kinase activity of IGF-1 receptor (IGF-1R), induces downstream MAPK/ERK and PI3K/Akt pathways, promotes the expression of cell cycle proteins (Cyclin D1, E), and accelerates the transition of cells from G1 phase to Sphase

More than 3 million people with Medicare could be eligible for the difficult-to-find and expensive weight-loss drug under new guidance which can cover the medication for patients who are obese or those who have a history of heart disease and are at risk of a heart attack or stroke

However, rapid weight loss can lead to loose skin, volume loss, and stubborn fat pockets, leading to a more aged look

E., Vatansev, H

Reddit communities like r/Ozempic show a consistent pattern: most users report losing 610 lbs by week 6, experiencing a noticeable plateau around week 4, and seeing appetite reduction (food noise) before significant scale movement